Kenneth L. Scott, Scott Powers Cancer Cell

Slides:

Advertisements

Similar presentations

Individualized Medicine from Prewomb to Tomb Eric J. Topol Cell Volume 157, Issue 1, Pages (March 2014) DOI: /j.cell Copyright.

Advertisements

Lessons from Hereditary Colorectal Cancer

What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell

Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr

Maintaining Cell Identity through Global Control of Genomic Organization Gioacchino Natoli Immunity Volume 33, Issue 1, Pages (July 2010) DOI: /j.immuni

Making Proteins in the Powerhouse B. Martin Hällberg, Nils-Göran Larsson Cell Metabolism Volume 20, Issue 2, Pages (August 2014) DOI: /j.cmet

Distribution of Human Embryonic Stem Cell Lines: Who, When, and Where Jennifer B. McCormick, Jason Owen-Smith, Christopher Thomas Scott Cell Stem Cell.

Eph-Ephrin Bidirectional Signaling in Physiology and Disease Elena B. Pasquale Cell Volume 133, Issue 1, Pages (April 2008) DOI: /j.cell

Extracellular Matrix Protein Anosmin Promotes Neural Crest Formation and Regulates FGF, BMP, and WNT Activities Yukinori Endo, Hiroko Ishiwata-Endo, Kenneth.

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.

The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes Tae-Min Kim, Peter W. Laird, Peter J. Park Cell Volume 155, Issue.

IPSC Crowdsourcing: A Model for Obtaining Large Panels of Stem Cell Lines for Screening Mahendra Rao Cell Stem Cell Volume 13, Issue 4, Pages (October.

Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.

Hedgehog Signaling Restrains Bladder Cancer Progression by Eliciting Stromal Production of Urothelial Differentiation Factors Kunyoo Shin, Agnes Lim, Chen.

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.

Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities Koen Schepers, Timothy B. Campbell, Emmanuelle Passegué Cell Stem Cell Volume.

Gastrulation Movements: the Logic and the Nuts and Bolts Maria Leptin Developmental Cell Volume 8, Issue 3, Pages (March 2005) DOI: /j.devcel

T-ALL: Home Is where the CXCL12 Is

Cancer: Inappropriate Expression of Stem Cell Programs?

Kristin G. Anderson, Ingunn M. Stromnes, Philip D. Greenberg

Jochen G. Schneider, Joseph H. Nadeau Cell Metabolism

Linking miRNA Regulation to BCR-ABL Expression: The Next Dimension

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Intravascular Survival and Extravasation of Tumor Cells

An Alternative Sugar Fuels AML

Mutant p53 gain of function: The NF-Y connection

Christian Grommes, Anas Younes Cancer Cell

Radiotherapy Complements Immune Checkpoint Blockade

Volume 9, Issue 2, Pages (August 2011)

Ana Magalhães, Henrique O. Duarte, Celso A. Reis Cancer Cell

Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle

Michael W.M. Kühn, Scott A. Armstrong Cancer Cell

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Next-Generation Sequencing: Methodology and Application

Communication in Drug Development: “Translating” Scientific Discovery

MDS Is a Stem Cell Disorder After All

Michael W.M. Kühn, Scott A. Armstrong Cancer Cell

Personalized Disease Models on a Chip

Volume 26, Issue 1, Pages 1-2 (July 2014)

Human Telomerase Caught in the Act

Doria Filipponi, Julius Muller, Alexander Emelyanov, Dmitry V. Bulavin

Pontine Infantile Glioma Simplified

New Views into the Genetic Landscape of Metastatic Breast Cancer

In This Issue Cell Volume 158, Issue 5, (August 2014)

Defining the Molecular Landscape of Ependymomas

Gliomas “Dope Up” for Growth

Circulating tumor DNA: Solid data from liquid biopsies

Putting Two Heads Together to Build a Better Brain

Treatment of hepatitis C

Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology

Cancer Genomes Evolve by Pulverizing Single Chromosomes

Common TLR5 Mutations Control Cancer Progression

Eukaryotic Transcription Activation: Right on Target

Characterizing the Killer Colorectal Carcinomas

Personalized Disease Models on a Chip

Kenneth L. Scott, Scott Powers Cancer Cell

The Reply The American Journal of Medicine

Shifting the Evolving CAR T Cell Platform into Higher Gear

Proteins in Plant Brassinosteroid Signaling

Bumping Up Kinase Activity with an ATP-Derived Neo-Substrate

Genome-Wide SNP Analysis in Cancer: Leukemia Shows the Way

A Missing Link in Genotype-Directed Cancer Therapy

A common pathway for genetic events leading to pheochromocytoma

It’s ALL in the Family: IKZF1 and Hereditary Leukemia

TFIID and MYB Share a Therapeutic Handshake in AML

Volume 10, Issue 3, Pages (September 2006)

Chapter 29 - Stem Cells and Generation of New Cells in the

There's a Time and a Place for MYCN

c-Raf in KRas Mutant Cancers: A Moving Target

Presentation transcript:

Functionally Assessing Candidate Drivers Advances Precision Cancer Medicine Kenneth L. Scott, Scott Powers Cancer Cell Volume 30, Issue 2, Pages 187-189 (August 2016) DOI: 10.1016/j.ccell.2016.07.011 Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 1 Approaches to Advancing Cancer Precision Medicine There are three general approaches that all converge upon advancing cancer precision medicine. The first approach, which is highlighted by the Berger et al. study in this issue of Cancer Cell, is to functionally validate new oncogenic drivers. This approach, coupled with the second approach of linking driver alterations to the response to existing cancer therapeutics, feeds into the continually evolving next-generation sequencing (NGS) diagnostic tests. The third approach, equally important, is to develop therapeutics to oncogenic drivers that have not yet been successfully targeted. Cancer Cell 2016 30, 187-189DOI: (10.1016/j.ccell.2016.07.011) Copyright © 2016 Elsevier Inc. Terms and Conditions